Trapollo and CareClix Launch Integration

ALEXANDRIA, VA / ACCESSWIRE, Feb 5, 2020 – (ACN Newswire) – CareClix, Inc., an industry leader in telemedicine, and Trapollo, a Cox Business company and a leading provider of Connected Health Services, announced today a Teaming Agreement for strategic collaboration to integrate their unique platforms supporting remote patient monitoring (RPM) programs. Working together to meet market demand for better access to quality healthcare at lower cost – the combination of CareClix and Trapollo delivers providers and payers with a customizable, end-to-end solution that supports scaled deployments for a broad range of corporate customers and consumers.

"We are proud to work with CareClix to expand our long track record of success and ensures that we continue to provide our stakeholders with leading technology and service solutions, including preferred access to the CareClix network of physicians to offer care through Trapollo clients," said Michael W. Braham, CEO of Trapollo.

"I am extremely excited about the opportunity that is in front of me and the CareClix team. We are delighted to partner with Trapollo to deliver remote patient monitoring services. With our proven track record of delivering hybrid telemedicine services to more than 7 million individuals, in conjunction with Trapollo and Cox Communications expertise, we intend to deliver a remote patient monitoring system that will be robust, affordable and simple for both the patient and provider. We aim to help patients achieve improved health outcomes for themselves and their families while providing new capabilities to physicians and their practices," said Dr John Korangy, CEO of CareClix Inc.

About Trapollo

Trapollo LLC, a Cox Business company, is a human-centric, leading end-to-end, connected healthcare company focused on improving patient care by mobilizing clinical engagement. Our goal is to help extend care past the walls of health systems by meeting people where they are in their day-to-day lives. Our broad range of remote health monitoring applications, products, and services go beyond technology – we are helping to improve the quality of care at every stage of life. By integrating and enabling more efficient clinician-to-patient communication and information, we help healthcare providers and payors focus on delivering care while improving health.

As part of the Cox Communications family of companies, Trapollo is dedicated to improving the quality of life across communities and is leveraging Cox's power of connectivity to bring technology where it is needed, providing more effective and continuous care. For more information, please visit our website: www.trapollo.com.

About CareClix

CareClix is a leading telemedicine solutions firm that provides software applications and a multispecialty medical network to a wide variety of health care services stakeholders. CareClix's suite of services is revolutionizing the way hospitals, doctors, and clinical care providers can interact with an increasing number of patients. CareClix Inc. is a wholly owned subsidiary of Solei Systems Inc. (OTC: SOLI). Learn more about CareClix by visiting our website: www.careclix.com.

About Solei

Solei Systems Inc is a fully reporting, fully audited public holding company in the health and wellness field with its primary focus on telemedicine. Currently, Solei Systems, Inc is comprised of two wholly owned subsidiaries: CareClix, Inc. and Clinical & Herbal Innovations, Inc www.soleihealth.com

Cautionary Statement Regarding Forward-Looking Information
This press release may contain certain "forward-looking statements" relating to the business of Solei Systems Inc. All statements, other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although Solei Systems, Inc believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Solei Systems, Inc's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Solei's periodic reports that are filed with the Securities and Exchange Commission and available on its website (www.sec.gov). All forward-looking statements attributable to Solei Systems or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

Contact
Solei Systems, Inc
206 N. Washington St. Suite 100
Alexandria, VA 22314
T: +1-703-832-4473
http://www.soleihealth.com
ir@soleihealth.com

SOURCE: Solei Systems, Inc.

Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Livingstone Health Unveils New Corporate Identity; Adds Cardiology and Family Medicine Capabilities

SINGAPORE, Feb 5, 2020 – (ACN Newswire) – Singapore-based Livingstone Health (formerly known as Ardmore Medical Group) has unveiled a new corporate identity after adding new capabilities and specialists to position itself as a holistic ASEAN-focused healthcare services player with at least five specialisations.

Following an internal reorganisation and rebranding, Livingstone has added Cardiology as a fourth specialisation and Family Medicine as a fifth, after Orthopaedic Surgery, Pain Management and Anaesthesiology, and Aesthetics and Wellness.

Dr Wilson Tay, Chief Executive Officer of Livingstone, said: "The new corporate identity reflects a bigger team with a clearer value proposition, offering a suite of medical specialisations that will raise our profile and positioning as a provider of healthcare services for ASEAN, a region of rapid economic growth."

Joining Dr Tay in executive leadership is Chief Business Officer Mr Dax Ng, Chief Operating Officer Dr Rachel Lim and Chief Medical Officer Dr Sebastian Chua.

The Cardiology practice, Livingstone Cardiology, is headed by Dr Ang Teck Kee, a Consultant and Interventional Cardiologist with more than 15 years of clinical experience. Livingstone Cardiology offers a comprehensive range of cardiac services from screening to treatment procedures. The clinic is located at Mount Elizabeth Medical Centre.

The fifth and latest healthcare discipline is Family Medicine, through a partnership between Livingstone and Phoenix Medical Group. The latter focuses mainly on primary healthcare such as chronic disease management and early prevention through its four clinics located across different parts of Singapore.

With the addition of Cardiology and Family Medicine, Livingstone's roster has grown from five to 11 doctors, and from 30 to 50 staff.

As part of its new business strategy, Livingstone will also offer design and operations consultancy services to third-party healthcare service providers to set up and operate medical centres in emerging ASEAN countries. On 19 November 2019, Livingstone successfully launched an aesthetics and wellness clinic in Phnom Penh, Cambodia – a joint-venture between Livingstone and Soriya Hospital, a leading healthcare provider in the country.

Dr Tay said, "We are pleased to welcome Phoenix Medical Group and all the new doctors to the Livingstone family. With the added expertise of Cardiology and Family Medicine, Livingstone is able to offer a more holistic service to our patients and also expand our footprint within Singapore and the larger Southeast Asia region."

The ASEAN healthcare landscape has changed very significantly since the 2008-2009 Global Financial Crisis. While patients once came to Singapore for specialist care, local costs have risen at a time when medical specialisation has improved in some parts of ASEAN, which groups 10 countries in Southeast Asia.

"We want to bring the Livingstone brand and medical expertise to patients in ASEAN countries. We have started this process through a partnership in Cambodia to offer health screening and aesthetics and wellness services. In Vietnam we have tied up with a local hospital to offer pain management services," said Dr Tay.

"We intend to build upon this track record to expand further across ASEAN. As we do so we also increase opportunities for doctors and specialists working under the Livingstone brand," he added.

About Livingstone Health

Livingstone Health is a Singapore-based multidisciplinary healthcare group specialising in Cardiology, Orthopaedic Surgery, Pain Management & Anaesthesiology, Aesthetics & Wellness, and Family Medicine.

The name "Livingstone" is derived from the succulent plant Lithops, which are often called "living stones". Both a stone and a plant, living stones symbolise Livingstone Health's resilience, growth and determination to be recognised as a trusted integrated healthcare provider for patients, as well as a centre of excellence of growth opportunities for medical professionals.

The Livingstone Health emblem is made up of a group of multi-coloured stones to represent its focus on multidisciplinary healthcare, while the trunk of the tree and its branches signify the vast and established network that connects these healthcare disciplines. For more information, please visit: www.livingstonehealth.com.sg

Media Contact:
Regine Lee
Marketing Assistant Manager
T: +65 6592 4855
E: hello@livingstonehealth.com.sg

Investor/Media Contact:
WeR1 Consultants Pte Ltd
Jordan Teo
T: +65 6737 4844
E: livingstone@wer1.net

Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Jacobson Pharma Launches First Influenza/RSV Home Diagnostic Kit in Hong Kong and Macau

HONG KONG, Feb 5, 2020 – (ACN Newswire) – Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Group"; Stock Code: 2633), a leading company engaged in research, development, production, marketing and sale of generic drugs and branded healthcare products, announced the launch of its first home diagnostic product for influenza/RSV under the brand name of "Dr. Freeman Flu/RSV Combo" (the "Product") in Hong Kong and Macau since January 2020. The product is available in different over-the-counter channels including major healthcare chain stores and drug stores.

Jacobson launches Dr. Freeman Flu/RSV Combo as its first influenza/RSV home diagnostic kit in the markets of Hong Kong and Macau. It is designed for qualitative determination of specific types of Influenza A and B virus and respiratory syncytial virus ("RSV") with test results available in 8 minutes.

Dr. Freeman Flu/RSV Combo is a handy one-step home diagnostic test designed for qualitative determination of specific types of Influenza A and B virus and respiratory syncytial virus ("RSV") with test results available in 8 minutes. The Product marks the first among others of its home diagnostic portfolio to be launched under the branded healthcare business platform of the Group. The Group is contemplating a potential strategic spin-off of its branded healthcare business which comprises proprietary medicines, proprietary Chinese medicines and branded health and wellness products such as health supplements, personal care products and diagnostic kits.

In scientific terms, Dr. Freeman Flu/RSV Combo uses monoclonal antibodies specific to the corresponding antigens of influenza and RSV for determination of the specific types of influenza and RSV infected, apart from the indication of the presence of influenza.

Mr Derek Sum, Chairman and Chief Executive Officer of Jacobson Pharma, commented, "We are very pleased for bringing in this useful home diagnostic product for influenza /RSV to the markets in Hong Kong and Macau. As a handy, speedy and specific self-diagnostic tool for the communicable disease, we believe the Product can highly benefit the public by helping influenza/RSV infected patients to seek prompt and effective medical treatment at the onset of the illnesses, especially during the peak flu seasons.

Bearing with the commitment to fulfilling unmet healthcare needs of consumers, we will continue to enhance our portfolio with high quality, innovative and well-trusted products in the expansion of our branded healthcare business as a strategic growth platform. Our ongoing efforts are set to strengthen our long-term strategic position and thereby enhancing the shareholders' values.".

About Jacobson Pharma Corporation Limited (Stock Code: 2633)
Jacobson Pharma is a leading generic drug company in Hong Kong. The Group's proprietary brand portfolio, notably being Po Chai Pills, Ho Chai Kung Tji Thung San, Contractubex Scar Gel, Flying Eagle Wood Lok Medicated Oil, Tong Tai Chung Woodlok Oil, Doan's Ointment, Saplingtan, Shiling Oil and Col-gan Tablet have been widely recognised by the market. The Group aims at the continued strategic enrichment of both of its generic drug and branded healthcare portfolios through the addition of high value-added products. With its corporate headquarters based in Hong Kong, the Group has also established its operating subsidiaries in China, Macau, Taiwan, Singapore and Cambodia forming a regional commercial platform to tap the market potential in the Asia Pacific and Greater China region. Jacobson Pharma has been a constituent stock of MSCI Hong Kong Micro Cap Index since 1 June 2017. For more details about Jacobson Pharma, please visit the Group's website:
http://www.jacobsonpharma.com

For media enquiries, please contact:
Strategic Financial Relations Limited
Vicky Lee Tel: (852) 2864 4834 Email: vicky.lee@sprg.com.hk
Stephanie Liu Tel: (852) 2864 4852 Email: stephanie.liu@sprg.com.hk
Rachel Ko Tel: (852) 2864 4806 Email: rachel.ko@sprg.com.hk
Fax: (852) 2527 1196

Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Swallowing difficulty may be caused by spinal disease, says study by Hong Kong Chiropractors

HONG KONG, Feb 3, 2020 – (ACN Newswire) – A stiff neck or difficulties swallowing could be caused by spinal degeneration, a new study suggests. Researchers found that changes in the spinal curvature could cause changes in swallowing, according to a study in the latest Journal of Clinical Medicine Insight, Case Studies.

Dr. Eric Chun-Pu Chu, chairman of Chiropractic Doctors Association of Hong Kong.

The study finds that "changes in spinal structure and functional dimension can impact the dimensions of the pharynx and cervical esophagus," said study leader Eric Chun-Pu Chu, chairman of Chiropractic Doctors Association of Hong Kong.

"The possible mechanisms of cervicogenic dysphasia, or difficulty in swallowing, include direct compression of the esophagus, impeded closure of the laryngeal inlet due to epiglottic tilt, paraesophageal inflammation, and upper esophageal sphincter spasms.

"Bad posture, such as kyphosis and scoliosis, could also be causing dysphagia," Chu said. "The predisposing factors include increasing age, short stature, and spinal abnormalities."

An elderly woman with neck stiffness and difficulty in swallowing solid foods and even liquids for 3 years sought chiropractic treatment in Hong Kong. She demonstrated a moderate hunch back and limited neck movement; her X-ray indicated misalignment of the first and second vertebrae and degeneration of the cervical spine.

The woman was diagnosed cervical spondylosis with a vertical atlantoaxial subluxation. Her therapeutic treatment consisted of stabilizing cervical subluxation and restoring joint mobility, with emphasis on cervical mobilization and strengthening exercises. After 20 sessions of chiropractic therapy, the woman had complete relief from neck problems and difficulty in swallowing.

Swallowing is a complex sensorimotor function. It is controlled by the brain stem (the medulla oblongata) and reflexes of the pharynx and esophagus. The aim of chiropractic treatment for this patient was to relieve the brainstem compression, stabilize the joint subluxation, stretch the shortened muscles, and mobilize the joint stiffness.

Still, the researchers note, it was possible that the woman experienced spontaneous recovery. However, the long-term clinical course prior to chiropractic intervention, the significant improvement of symptoms, and post-treatment radiographic parameters weigh against such coincidental effects.

The study finds that, though an interpretation of the findings, patients experiencing swallowing difficulty and cervical subluxation respond well to chiropractic treatment.

SOURCE: Journal of Clinical Medicine Insight: Case Reports, December 2019.
www.cda.org.hk/index.php/news_f/detail?lang=en&id=309

Dr Eric Chun-Pu Chu
Chairman@cda.org.hk
Chiropractic Doctors Association of Hong Kong

Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Orders for NatShield(TM) Sanitizer Disinfectant Spike after Outbreak of Coronavirus

KUALA LUMPUR/PERTH, Jan 29, 2020 – (ACN Newswire) – ASX-listed Holista CollTech (ASX:HCT, "Holista") announced today a strong spike in demand in Malaysia for it all-natural disinfectant spray NatShield(TM) Sanitizer, that contains the powerful Path-Away(R) anti-microbial compound. The increased demand follows the recent outbreak of the deadly coronavirus originating from Wuhan, China.

NatShield

Letter from Malaysian MOH

Holista confirmed that since mid-January 2020 it had sold out all NatShield(TM) Sanitizer in its inventory. Each bottle of NatShield(TM) Sanitizer contains 5% of Path-Away(R) which is made from natural plant-based substances that have been approved for use by the U.S. Food and Drug of Authority and tested by World Health Organization ("WHO") approved laboratories in numerous countries around the world.

Developed by Global Infection Control Consultants LLC ("GICC LLC") based in South Carolina, USA, Path-Away(R) (www.path-away.com) is distributed in Malaysia by Holista as NatShield(TM) Sanitizer. Holista is the exclusive distributor of Path-Away(R) for the ASEAN region. ASEAN countries with confirmed cases of the coronavirus include Malaysia, Singapore, Thailand and Cambodia.

Based on requests from seven chains representing over 3,000 pharmacies in Malaysia, Holista has ordered 60,000 bottles of NatShield(TM) Sanitizer to be air-freighted to Malaysia from the U.S.A. by mid-February.

The novel coronavirus was first reported to WHO on 31 December 2019 and has been under investigation ever since. Countries with confirmed infections include the U.S.A., Canada, France, Australia, Japan, South Korea and Nepal.

The active substance in the spray weakens the cell walls of the virus, causing the infectious organisms to clump together, in the process killing themselves, almost instantly. The potent compound is environmentally safe with very low toxicity and hence is not harmful to humans and pets even if accidentally swallowed. It is free of alcohol and other potentially toxic chemicals.

It is approved for use by Malaysia's Ministry of Health, with special reference to the H1N1 virus – another coronavirus, similar to one in this outbreak which led to more than 70 deaths in 2009. It has also been approved by the Food and Safety Authority of New Zealand, and the New Zealand Environmental Protection Authority ("EPA"). It is also approved by the United States Pharmacopeia ("USP") and has undergone successful USP-51 testing as a disinfectant.

"This is not a drug. It acts by sanitising body parts. It had been consistently shown to be effective and safe to users and the environment in the most advanced biosafety laboratories in the world," said Dr Rajen Manicka, the CEO of Holista which is headquartered in Kuala Lumpur, Malaysia and listed on the Australian Securities Exchange ("ASX").

"NatShield(TM) Sanitizer was created to treat previously known coronaviruses. It can be used as a precautionary spray in crowded areas including public transport. Three to five sprays are all that is needed to disinfect hands, toilet seats, doorknobs, countertops and trolley bars, with efficacy lasting up to two hours. We plan to sell it in all infected ASEAN countries," he said.

Dr Arthur Martin, the President of GICC LLC (www.giccllc.com) said, "The Path-Away(R) formula has been proven in world-renowned laboratories including those working with WHO, to be able to kill over 170 deadly pathogens including previously existing forms of coronaviruses. Path-Away(R) is currently undergoing testing on the newly emerged coronavirus designated as the "Wuhan Virus."

Dr Martin is a globally respected scientist and a member of the WHO's Stop Tuberculosis ("T.B."). Board who had been previously nominated for the prestigious "Kochon Prize" for his work on T.B. "Humans of all ages can use Path-Away(R) with little or no risk of toxic effects. It retains its efficacy for hours even under extremes of temperature and is not corrosive and can be used even in sensitive installations," he said.

Contact:
Corporate Affairs & Business Opportunities
Dr Rajen Manicka: rajen.m@holistaco.com
General Enquiries: enquiries@holistaco.com

Media and Investor Relations:
WeR1 Consultants Pte Ltd
Karishma Ailsinghani
E: holista@wer1.net; P: +65 84792656

About Holista CollTech Ltd

Holista CollTech Ltd ("Holista") is a research-driven biotech company, the result of a merger between Holista Biotech Sdn Bhd and CollTech Australia Ltd. Headquartered in Perth and with extensive operations in Malaysia, the company is dedicated to delivering first-class natural ingredients and wellness products globally. Holista is a leader in the research of herbs and ingredients for the making of healthier food.

Listed on the Australian Securities Exchange ("ASX"), Holista researches, develops, manufactures and markets "health-style" products to address the unmet and evolving needs of natural medicine. Holista's suite of ingredients, among other things, includes low-GI baked products, reduced-sodium salts, low-fat fried foods and low calories sugar without compromising taste, odour and mouthfeel. Holista remains the only company to produce sheep (ovine) collagen using patented extraction methods. For more information, please refer to http://www.holistaco.com

Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

New Disinfectant Stops Spread of Virus, Including Coronavirus Strain from China

SYDNEY, Jan 24, 2020 – (ACN Newswire) – Australian researcher Steven Kritzler says his Evocide Extra disinfectant is able to stop the spread of virus, as in the present outbreak in Wuhan City, China. This new strain of Coronavirus is a SARS-like virus that has caused hundreds of infections in China, and has spread to Thailand, Japan and South Korea.

Steven Kritzler of Novapharm Research (Aus) Pty. Ltd.

"Both the Wuhan virus, known as 2019-nCoV, and SARS belong to the family of viruses known as Coronaviridae, which can be deactivated by many materials, such as Evocide Extra," says Kritzler, who is based at Novapharm Research near Sydney, and is a committee member of the Australian Therapeutic Goods Administration (TGA).

Kritzler garnered attention at the Symposium on Advanced Infection Control in November when his Evocide Extra disinfectant formulation was presented. "Coronavirus is a type of enveloped virus — a virus that develops viruses. My formulation can deactivate any virus, including enveloped and non-enveloped viruses."

"Coronavirus is microscopic, hence face masks alone cannot effectively prevent spreading the virus. I suggest that the best way to protect from spreading the virus is to wash your hands regularly, for example when you touch the door handle. And remember to use the disinfectants in time," says Kritzler.

Southern Cross, another formulation by Kritzler, are eco-friendly skin and hard surface disinfectant paper wipes that can deactivate viruses such as HIV (human immunodeficiency virus), hand-foot-mouth (EV71), influenza A (H1N1) and measles, and like Evocide can kill 99.999% of bacterial pathogens including super bacteria.

The Chinese Spring Festival holiday begins later this week, increasing the risk of spread of the new virus. The holiday period typically sees hundreds of millions of Chinese traveling throughout the country and overseas.

Contact: Kenny Kang, kz@fromau.com
Southern Cross Biotechnology Pty Ltd.

Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

New Disinfectant Stops Spread of Virus, Including Coronavirus Strain from China

SYDNEY, Jan 23, 2020 – (ACN Newswire) – Australian researcher Steven Kritzler says his new Evocide disinfectant is able to stop the spread of virus, such as the present outbreak in Wuhan City, China. This new strain of Coronavirus is a SARS-like virus that has caused hundreds of infections in China, and has spread to Thailand, Japan and South Korea. Symptoms include fever, cough or chest tightness, and difficulty breathing.

"Both the Wuhan virus, known as 2019-nCoV, and SARS belong to the family of viruses known as Coronaviridae, which are not strong and can be deactivated by many materials," says Kritzler, who is based at Novapharm Research near Sydney, and is a committee member of the Australian Therapeutic Goods Administration (TGA).

Kritzler garnered attention at the Hong Kong Symposium on Advanced Infection Control in November when he presented his new Evocide Extra disinfectant. "Coronavirus is a type of enveloped virus — a virus that develops viruses. My formulation can deactivate any virus, including enveloped and non-enveloped viruses."

"Coronavirus is microscopic, hence face masks alone cannot effectively prevent spreading the virus. I suggest that the best way to protect from spreading the virus is to wash your hands regularly, for example when you touch the door handle. And remember to use the disinfectants in time," says Kritzler.

Southern Cross Paper is another formulation by Kritzler. He explains these bio-degradable, eco-friendly paper wipes can deactivate viruses such as rabies virus, HIV (human immunodeficiency virus), hand-foot-mouth virus (EV71), influenza A (H1N1) and measles virus, and can kill 99.999% bacterial and fungal pathogens including super bacteria.

The Chinese Spring Festival holiday begins later this week, increasing the risk of spread of the new virus. The holiday period typically sees hundreds of millions of Chinese traveling throughout the country and overseas.

Contact: Kenny Kong, kz@fromau.com
Southern Cross Biotechnology Pty Ltd.

Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com